Not Signed In -
Exercise |
|
|
Clinical Trial: A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
This study is not yet open for patient recruitment.
Verified by Alberta Cancer Board December 2005
Purpose
This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.
| Condition | Intervention | Phase |
|---|---|---|
| -Prostatic Neoplasms -Neoplasm Metastasis -Palliative Care | Behavior: Exercise training | Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapies; Prostate Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Further study details as provided by Alberta Cancer Board:
Primary Outcomes: -feasibility (recruitment, adherence, safety)
Secondary Outcomes: -quality of life; -functional abilities
Expected Total Enrollment: 30
Secondary Outcomes: -quality of life; -functional abilities
Expected Total Enrollment: 30
Study start: February 2006
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Male
Criteria
Inclusion Criteria:
- diagnosis of prostate cancer
- receiving docetaxel-based chemotherapy at the CCI
- age 18 years or over
- approval of oncologist
- informed written consent
Exclusion Criteria:
- life expectancy less than 6 months
- Karnofsky performance score less than 70
- contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
- unable to understand, read, write and speak English
- unable or unwilling to attend supervised exercise sessions 3 times weekly
- unable or unwilling to complete outcome assessments
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00271687
Clare Stevinson, PhD 780 492 2663 Clare.Stevinson@ualberta.ca
Canada, Alberta
Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada
Paula Langenhoff, B.H.A. 780-432-8909 paulalan@cancerboard.ab.ca
Clare Stevinson, PhD, Sub-Investigator
Clare Stevinson, PhD, Sub-Investigator
Study chairs or principal investigators
Kerry Courneya, M.D., Principal Investigator, Cross Cancer Institute
More Information
Study ID Numbers: SP-14-0049
Last Updated: January 3, 2006
Record first received: December 30, 2005
ClinicalTrials.gov Identifier: NCT00271687
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2006-01-10
Last Updated: January 3, 2006
Record first received: December 30, 2005
ClinicalTrials.gov Identifier: NCT00271687
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2006-01-10
email this page
print this page
bookmark this page
feedback on this page
